Drug Trial Radar · NCT06085521
A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Oct 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Jan 26, 2022
Primary completion
Jun 14, 2023
Study completion Jun 14, 2023
Sponsor
- Lead sponsor
- Lynk Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.
Conditions
- Atopic Dermatitis
Interventions
LNK01001 Dose ADrug
Capsules taken orally
LNK01001 Dose BDrug
Capsules taken orally
placeboDrug
Capsules taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Eczema Area and Severity Index (EASI) ScoreTime frame: week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jianzhong Zhang
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.